| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 02/27/2002 | EP1182210A1 Epitopes of tumor-associated MUC1 antigen |
| 02/27/2002 | EP1181938A2 Rapamycin conjugates and antibodies |
| 02/27/2002 | EP1181549A1 Protein-protein interactions |
| 02/27/2002 | EP1181390A1 27 human secreted proteins |
| 02/27/2002 | EP1181385A2 Modulation of gene expression in gastrointestinal inflammation |
| 02/27/2002 | EP1181369A1 Four-helical bundle protein zsig81 |
| 02/27/2002 | EP1181367A2 Polynucleotides and membrane-bound polypeptides encoded thereby |
| 02/27/2002 | EP1181366A1 Mammalian receptor proteins; related reagents and methods |
| 02/27/2002 | EP1181365A1 PrP-LIKE GENE |
| 02/27/2002 | EP1181320A2 Somatic transgene immunization and related methods |
| 02/27/2002 | EP1181319A1 Dr4 antibodies and uses thereof |
| 02/27/2002 | EP1181318A2 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules |
| 02/27/2002 | EP1181317A1 An integrin heterodimer and an alpha subunit thereof |
| 02/27/2002 | EP1181316A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS |
| 02/27/2002 | EP1181315A1 LAWSONIA DERIVED GENE AND RELATED FlgE POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES |
| 02/27/2002 | EP1181306A1 Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis |
| 02/27/2002 | EP1181303A1 50 human secreted proteins |
| 02/27/2002 | EP1181058A2 Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides |
| 02/27/2002 | EP1181056A1 Lim mineralization protein splice variants |
| 02/27/2002 | EP1181054A1 A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
| 02/27/2002 | EP1181050A1 Methods for preventing reactivation of latent virus and controlling virus replication |
| 02/27/2002 | EP1181037A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 02/27/2002 | EP1180938A2 Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
| 02/27/2002 | EP0858509B1 Dna sequences encoding cmh-1, a cysteine protease involved in apoptosis |
| 02/27/2002 | EP0836380B1 Fgf9 as a specific ligand for fgfr3 |
| 02/27/2002 | EP0786087B1 Polypeptide-dendrimer complexes |
| 02/27/2002 | CN1337883A Tumor necrosis factor antagonists and their use in endometriosis |
| 02/27/2002 | CN1337405A Sodium-ion drived chlorine-ion/exchange protein bicarbonate |
| 02/27/2002 | CN1337404A Short-chain nervous cobratoxin and its prepn and use |
| 02/26/2002 | US6350861 A site directed mutagenic immunoglobulin having a mutations in the variable region that changes the glycosylation pattern; diagnosis and therapy for autoimmune diseases, cancers and viral diseases |
| 02/26/2002 | US6350860 An engineered antibody constructs, consisting of humanized single-chain fv fragments, diabodies, triabodies, tetravalent antibodies, peptabodies and hexabodies; diagnosis and therapy for septic shock, cachexia, multiple sclerosis and psoriasis |
| 02/26/2002 | US6350858 A polypeptide involved in controlling phosphate retention; diagnosis and therapy for chronic kidney failure, end stage kidney disease, uremic bone disease, and cancer |
| 02/26/2002 | US6350857 Fifty-four homologue (ffh) from streptococcus pneumoniae |
| 02/26/2002 | US6350854 Isolated 55 to 72 kDa protein which binds to prion proteins |
| 02/26/2002 | US6350730 OB polypeptides and modified forms as modulators of body weight |
| 02/26/2002 | US6350603 Phosphodiesterase 10 |
| 02/26/2002 | US6350598 MurD |
| 02/26/2002 | US6350593 Receptors for fibroblast growth factors |
| 02/26/2002 | US6350581 Tumor-associated antigen |
| 02/26/2002 | US6350452 Composition comprising antibody immunoreactive with neoepitope produced in cell undergoing apoptosis, said neoepitope comprising amino terminus produced by cleavage of protein at cleavage site cleaved by protease during apoptosis |
| 02/26/2002 | US6350450 Isolated antibody which specifically binds to mammalian nl1 tie ligand polypeptide which has specified amino acid sequence and is capable of inducing vascularization |
| 02/26/2002 | US6350446 Polypeptides with amino acid sequences for kidney failure |
| 02/26/2002 | CA2038030C Synthetic peptides which contain sequences from factor viia, and the use thereof |
| 02/25/2002 | CA2315900A1 Apple mads-box protein, gene encoding said protein, antibody against said protein, method for detecting transcript of said gene or protein expressed therefrom and process for preparing transgenic plant containing said gene |
| 02/21/2002 | WO2002014870A2 Use of antibodies against specific mhc-peptide complexes |
| 02/21/2002 | WO2002014522A1 Pyruvate:nadp+ oxidoreductase and uses thereof |
| 02/21/2002 | WO2002014511A2 Regulation of human p2y1-like g protein-coupled receptor |
| 02/21/2002 | WO2002014500A2 Human genes and gene expression products |
| 02/21/2002 | WO2002014499A2 Claudin polypeptides |
| 02/21/2002 | WO2002014489A2 Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof |
| 02/21/2002 | WO2002014485A2 Kallikrein gene |
| 02/21/2002 | WO2002014470A2 Expression of herstatin, an alternative her-2/neu product, in cells that express either p185her-2 or the egf receptor inhibits receptor activity and cell growth |
| 02/21/2002 | WO2002014467A2 Cng2b: a putative human cyclic nucleotide-gated ion channel |
| 02/21/2002 | WO2002014371A1 Fv constructs with an influenceable affinity for a substance that is to be linked |
| 02/21/2002 | WO2002014369A2 Human kininogen d5 domain polypeptides and their use |
| 02/21/2002 | WO2002014366A2 Genes involved in immune related responses observed with asthma |
| 02/21/2002 | WO2002014361A2 NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER |
| 02/21/2002 | WO2002014355A2 Novel mitogen activated kinase |
| 02/21/2002 | WO2002014352A2 Therapeutic compounds for ovarian cancer |
| 02/21/2002 | WO2002014348A2 Glycoproteins and methods of use thereof |
| 02/21/2002 | WO2002013865A1 Agents for ameliorating symptoms caused by joint diseases |
| 02/21/2002 | WO2002013862A2 Method and composition for altering a b cell mediated pathology |
| 02/21/2002 | WO2002013860A1 Stabilized antibody-containing preparations |
| 02/21/2002 | WO2002013859A1 Method of inhibiting antibody-containing solution from coagulating or becoming turbid |
| 02/21/2002 | WO2002013845A2 Inflammation related g-protein coupled receptor |
| 02/21/2002 | WO2002013763A2 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists |
| 02/21/2002 | WO2001080885A3 Equine protozoal myeloencephalitis vaccine |
| 02/21/2002 | WO2001079443A3 Albumin fusion proteins |
| 02/21/2002 | WO2001072977A3 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 02/21/2002 | WO2001072334A3 Methods for treating disease with antibodies to cxcr3 |
| 02/21/2002 | WO2001070807A3 G-protein associated molecules |
| 02/21/2002 | WO2001068846A3 Transcription activator of the cited family |
| 02/21/2002 | WO2001066747A8 Proteins named fctrx and nucleic acids encoding same |
| 02/21/2002 | WO2001058484A3 Novel uses of mammalian ccr8 receptors and related reagents |
| 02/21/2002 | WO2001057535A3 Analytical method to evaluate animal models of neurofibrillary degeneration |
| 02/21/2002 | WO2001055391A3 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer |
| 02/21/2002 | WO2001055319A3 Endocrine related nucleic acids, proteins and antibodies |
| 02/21/2002 | WO2001053338A3 Cbp86, a sperm specific protein |
| 02/21/2002 | WO2001051629A3 Circularly permutated, interaction-activated proteins |
| 02/21/2002 | WO2001046397A3 Human kinases |
| 02/21/2002 | WO2001046232A3 Soluble interleukin-20 receptor |
| 02/21/2002 | WO2001044282A3 Bcl-g polypeptides, encoding nucleic acids and methods of use |
| 02/21/2002 | WO2001032871A3 Follistatin-related protein zfsta4 |
| 02/21/2002 | WO2001031005A3 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 02/21/2002 | WO2001030300A3 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 02/21/2002 | US20020022720 Anti-TNF antibodies and peptides of human tumor necrosis factor |
| 02/21/2002 | US20020022718 Genes identified as required for proliferation of E. coli |
| 02/21/2002 | US20020022717 Using monoclonal antibodies |
| 02/21/2002 | US20020022595 Treating inflammation resulting from a response of the non-specific defense system in a mammal by administering an antiinflammatory agent and the uncontaminated Mac-1 alpha subunit |
| 02/21/2002 | US20020022266 Coupling compound to tissue |
| 02/21/2002 | US20020022254 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 02/21/2002 | US20020022241 Detecting preferential immunoglobulins in solution; provide solid support, immoblize squalene on support, wash with blocking agent, incubate with test sample, incubate with ligand, incubate with indicator, detect indicator |
| 02/21/2002 | US20020022228 Evaluating nucleotide sequence maintenance; provide nucleotide sequences, incubate with maintenance enzymes, monitor nucleotide sequence for enzymatic removal of preferential nucleotide sequences |
| 02/21/2002 | US20020022216 Preferential propagation of target cells; mix cells with propagation nutrients, monitor cell propagtion, recover preferential cells |
| 02/21/2002 | US20020022033 Diagnosis of Aids |
| 02/21/2002 | US20020022031 Immunotherapy for chronic myelocytic leukemia |
| 02/21/2002 | US20020022030 Product and process for regulation of T cell responses |
| 02/21/2002 | US20020022028 Integrin antagonist; bone disorders |
| 02/21/2002 | US20020022023 Treatment of diabetes mellitus and insulin receptor signal transduction |
| 02/21/2002 | US20020022020 Induction lymphocyte tolerance |